Patent intelligence · US
US 11850264
Gamma delta T-cell receptor and its ligand
Gamma delta T-cell receptor and its ligand
Patent details — US 11850264
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 26, 2023
- Expiration
- Dec 21, 2043
- Claims
- 20
- CPC classes
- A61K, A61K40/11, A61K40/32, A61K40/42
Quick answer
US 11850264 (Gamma delta T-cell receptor and its ligand) is held by University College Cardiff Consultants Limited. Status: granted. Granted Dec 26, 2023. Expires Dec 21, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K40/11, A61K40/32, A61K40/42, A61K45/06, A61P
More from University College Cardiff Consultants Limited
Related pharmaceutical patents in our USPTO index.
-
US 12383540
Compounds that modulates AMPA receptor function
granted -
US 12318418
Modified adenoviruses
granted -
US 12263173
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12144813
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12053513
Cancer-specific T-cell receptors
granted -
US 11957677
Cancer treatment using FGFR inhibitors and PLK1 inhibitors
granted -
US 11725039
α/β t-cell receptor and methods of using it
granted
Frequently asked questions
What is US patent 11850264?
US 11850264 (Gamma delta T-cell receptor and its ligand) is held by University College Cardiff Consultants Limited. Status: granted. Granted Dec 26, 2023. Expires Dec 21, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11850264?
University College Cardiff Consultants Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 11850264 expire?
Our index shows an expiration date of Dec 21, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.